TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo December 7, 2023 Keith Goldan Chief Financial Officer Syndax Pharmaceuticals Inc 35 Gatehouse Drive, Building D, Floor 3 Waltham, Massachusetts 02451 Re: Syndax Pharmaceuticals Inc Form 10K for Fiscal Year Ended December 31, 2022 File No. 001-37708 Dear Keith Goldan: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences